Effect of granulocyte colony-stimulating factor on neutropenia in liver transplant recipients with hypersplenism.
The authors present details of their initial experience with use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) for preventing neutropenia caused by hypersplenism, and, possibly, for reducing the risk of postoperative infections in pediatric liver transplant recipients. Seven patients with end-stage liver disease, three of whom had severe hypersplenism, underwent living related liver transplantation (LRLT). The rhG-CSF was administered to the latter three patients. Peripheral neutrophil counts decreased immediately after reperfusion (to 1500 +/- 300/microL) in the three patients, and returned to normal with use of rhG-CSF 3 to 10 days after transplantation. The dosage was adjusted to maintain peripheral leukocyte and granulocyte counts above 5,000/microL and 2,000/microL, respectively. This initial clinical trial showed that rhG-CSF administration restores the leukocyte counts of patients who have hypersplenism, without any significant adverse effects, and that rhG-CSF holds promise for reducing the risk of infections after liver transplantation.
Ishizone
S
S
First Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Makuuchi
M
M
Kawasaki
S
S
Matsunami
H
H
Terada
M
M
Kitahara
S
S
Kamada
N
N
Nakahata
T
T
Kawarasaki
H
H
Iwanaka
T
T
D002648:Child; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D006971:Hypersplenism / Q000150:complications*; D007223:Infant; D007958:Leukocyte Count; D008107:Liver Diseases / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D009503:Neutropenia / Q000097:blood / Q000209:etiology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor